Barinthus Biotherapeutics plc.
BRNSDelisted Sep 9, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001828185
Barinthus Biotherapeutics plc. was delisted on Sep 9, 2026; its insiders filed their last Form 4 on Sep 11, 2026; 15 institutions reported holding it in 13F filings for Q2 2026, worth $7.84M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Barinthus Biotherapeutics plc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Barinthus Biotherapeutics plc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Oxford Science Enterprises plc | Other: former 10% owner | 0 | Sep 11, 2026 | 1 |
| Wright Robin | Director | 0 | Sep 9, 2026 | 1 |
| Scheeren Joseph | Director | 0 | Sep 9, 2026 | 1 |
| Phillips Anne M. | Director | 0 | Sep 9, 2026 | 1 |
| Morgon Pierre A. | Director | 0 | Sep 9, 2026 | 1 |
| Hooftman Leon | Chief Medical Officer | 0 | Sep 9, 2026 | 1 |
| Hammacher Alex | Director | 0 | Sep 9, 2026 | 1 |
| Enright William | Chief Executive Officer | 0Indirect | Sep 9, 2026 | 1 |
| Dawes Karen A | Director | 0 | Sep 9, 2026 | 1 |
| Griffiths Graham | Chief Business Officer | 104,209 | Feb 5, 2025 | 0 |
| Brown Gemma | Chief Financial Officer | – | Feb 5, 2025 | 0 |
| Pelletier Nadege | Chief Scientific Officer | – | Jan 4, 2024 | 0 |
| Marshall Margaret | Chief Medical Officer | – | Mar 29, 2023 | 0 |
| Evans Thomas George | Fmr Chief Scientific Officer | – | Mar 29, 2023 | 0 |
| Ellis Christopher | Chief Operating Officer | 75 | Feb 23, 2023 | 0 |
| M&G Investment Management Ltd | 10% Owner | 5,197,349Indirect | Oct 4, 2022 | 0 |
| M&G Alternatives Investment Management Ltd | 10% Owner | 0Indirect | Oct 4, 2022 | 0 |
| Egorov Georgy | Chief Financial Officer | – | Feb 11, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 28, 2023 (view filing) | Jun 26 | 2 days | Scheeren JosephDirector | PPurchase | +10.0K | $2.44 | +$24.4K | +76.9%23.0K after | |
| Jun 1, 2023 (view filing) | May 25 | 7 daysLate | Wright RobinDirector | PPurchase | +13.8K | $2.66 | +$36.6K | +39.8%48.3K after | |
| Mar 29, 2023 (view filing) | Mar 27 | 2 days | Enright WilliamChief Executive Officer | SSale | −15.0K | $2.42 | −$36.3K | −2.0%728.5K after | |
| Aug 26, 2022 (view filing) | Aug 25 | 1 day | Griffiths GrahamChief Business Officer | SSale | −10.0K | $7.39 | −$73.9K | −8.8%104.2K after | |
| Aug 26, 2022 (view filing) | Aug 24-25 | 2 days | Ellis ChristopherChief Operating Officer | SSale | −39.6K | $6.55 | −$259.6K | −99.8%75 after | 3 lots |
| Aug 19, 2022 (view filing) | Aug 17-18 | 2 days | Ellis ChristopherChief Operating Officer | SSale | −2.82K | $4.82 | −$13.6K | −97.4%75 after | 2 lots |
| Aug 19, 2022 (view filing) | Aug 17 | 2 days | Griffiths GrahamChief Business Officer | SSale | −500 | $4.76 | −$2.38K | −0.4%114.2K after | |
| Aug 17, 2022 (view filing) | Aug 15-16 | 2 days | Ellis ChristopherChief Operating Officer | SSale | −7.55K | $4.77 | −$36.0K | −99.0%75 after | 2 lots |
| Aug 17, 2022 (view filing) | Aug 15-16 | 2 days | Griffiths GrahamChief Business Officer | SSale | −3.62K | $4.77 | −$17.3K | −3.1%114.7K after | 2 lots |
| Aug 15, 2022 (view filing) | Aug 12 | 3 days | Griffiths GrahamChief Business Officer | SSale | −5.00K | $4.50 | −$22.5K | −4.1%118.3K after | |
| Jul 15, 2022 (view filing) | Jun 28 | 17 daysLate | Ellis ChristopherChief Operating Officer | SSale | −5 | $6.00 | −$30 | −6.3%75 after | |
| Jul 15, 2022 (view filing) | Jun 23 | 22 daysLate | Griffiths GrahamChief Business Officer | SSale | −8 | $5.28 | −$42.24 | 0.0%123.2K after | |
| Apr 4, 2022 (view filing) | Apr 1 | 3 days | Scheeren JosephDirector | PPurchase | +10.0K | $5.09 | +$50.9K | +333.3%13.0K after | |
| Apr 4, 2022 (view filing) | Mar 31 | 4 days | Hammacher AlexDirector | PPurchase | +2.00K | $5.14 | +$10.3K | +200.0%3.00K after | |
| Jan 4, 2022 (view filing) | Dec 31, 2021 | 4 days | Hammacher AlexDirector | PPurchase | +1.00K | $10.86 | +$10.9K | New position1.00K after | |
| Dec 23, 2021 (view filing) | Dec 22 | 1 day | Wright RobinDirector | PPurchase | +10.0K | $9.97 | +$99.7K | +40.8%34.5K after |